GB0907973D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
GB0907973D0
GB0907973D0 GBGB0907973.2A GB0907973A GB0907973D0 GB 0907973 D0 GB0907973 D0 GB 0907973D0 GB 0907973 A GB0907973 A GB 0907973A GB 0907973 D0 GB0907973 D0 GB 0907973D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0907973.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modern Biosciences Ltd
Original Assignee
Modern Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modern Biosciences Ltd filed Critical Modern Biosciences Ltd
Priority to GBGB0907973.2A priority Critical patent/GB0907973D0/en
Publication of GB0907973D0 publication Critical patent/GB0907973D0/en
Priority to PCT/GB2010/000926 priority patent/WO2010128309A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0907973.2A 2009-05-08 2009-05-08 Combination therapy Ceased GB0907973D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0907973.2A GB0907973D0 (en) 2009-05-08 2009-05-08 Combination therapy
PCT/GB2010/000926 WO2010128309A1 (en) 2009-05-08 2010-05-07 Combination therapy comprising a taxane and a sigma receptor ligand sauch as rimcazole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0907973.2A GB0907973D0 (en) 2009-05-08 2009-05-08 Combination therapy

Publications (1)

Publication Number Publication Date
GB0907973D0 true GB0907973D0 (en) 2009-06-24

Family

ID=40833723

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0907973.2A Ceased GB0907973D0 (en) 2009-05-08 2009-05-08 Combination therapy

Country Status (2)

Country Link
GB (1) GB0907973D0 (en)
WO (1) WO2010128309A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190142840A1 (en) * 2016-06-06 2019-05-16 Esteve Pharmaceuticals, S.A. Use of sigma receptor ligands in cancer
WO2025031979A1 (en) 2023-08-04 2025-02-13 Kyrexa Ltd Use of rimcazole to treat cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK460879A (en) 1978-11-01 1980-05-02 Wellcome Found METHOD FOR PREPARING 9- (3- (3,5-CISDIMETHYLPIPERAZINO) PROPYL) CARBAZOL A SALT OR A SOLVATE OF SUCH A SALT
FR2629819B1 (en) 1988-04-06 1990-11-16 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF BACCATIN III AND DESACETYL-10 BACCATIN III DERIVATIVES
FR2629818B1 (en) 1988-04-06 1990-11-16 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF TAXOL
US5175315A (en) 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
GB9814036D0 (en) 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
FR2887454B1 (en) * 2005-06-28 2009-06-05 Sanofi Aventis Sa ANTITUMOR COMBINATIONS CONTAINING DERIVATIVES OF TAXANE AND SIGMA LIGANDS
RU2537226C2 (en) * 2008-02-18 2014-12-27 Лабораторьос Дель Др. Эстеве, С.А. Using compounds binding to sigma receptor ligands for treating neuropathic pain progression caused by chemotherapy

Also Published As

Publication number Publication date
WO2010128309A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
IL206654A0 (en) Combination therapy
IL222481A0 (en) Combination therapy
EP2552323A4 (en) Combination therapy
GB0908957D0 (en) Therapeutic agents
GB0900599D0 (en) Treatment
GB0900484D0 (en) Therapeutic agent
GB201013898D0 (en) Well treatment
GB0913968D0 (en) Treatment
GB0915319D0 (en) Combination medicament
GB0916997D0 (en) Combination therapy
GB201001521D0 (en) Treatment
GB0803948D0 (en) Combination therapy
GB0907973D0 (en) Combination therapy
EP2629766A4 (en) Combination therapy
GB0910493D0 (en) Therapeutic agents
GB0906026D0 (en) Therapeutic compounds
GB0921244D0 (en) Therapy
GB0914820D0 (en) WATerian therapy
GB0903321D0 (en) Therapy
GB0903319D0 (en) Therapy
GB0922098D0 (en) Therapeutic use
GB0813292D0 (en) Therapy
GB0812659D0 (en) Therapy
PH32009000130S1 (en) Sunbed
PH32009000132S1 (en) Sunbed

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)